简介内容：JB170, a potent and highly specific PROTAC-mediated AURORA-A (Aurora Kinase) degrader (DC50=28 nM), achieves its selectivity by linking Alisertib to the Cereblon-binding molecule Thalidomide. It demonstrates a strong preference for AURORA-A (EC50=193 nM) over AURORA-B (EC50= ?M). The mechanism of JB170 involves S-phase arrest, specifically through AURORA-A depletion, and it is notably effective in inhibiting the non-catalytic functions of AURORA-A kinase [1].
Customer Service
